Obesity and the gastroenterologist

Endoscopy

Volumn 41, Issue 7, 2009, Pages 608-611

  Mathus Vliegen, E M H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BALLOON; BARIATRIC SURGERY; BODY MASS; DIGESTIVE SYSTEM DISEASE; HUMAN; NOTE; OBESITY;

BARIATRIC SURGERY; BODY MASS INDEX; DIGESTIVE SYSTEM DISEASES; GASTRIC BALLOON; HUMANS; OBESITY;

EID: 70249138389     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0029-1214889     Document Type: Review

References (48)

1. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096
2. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
3. Mathus-Vliegen EM. The role of endoscopy in bariatric surgery. Best Pract Res Clin Gastroenterol 2008; 22: 839-864
4. Christou NV, Sampalis JS, Liberman M et al. Surgery decreases longterm mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416-423
5. Stellato TA, Crouse C, Hallowell PT. Bariatric surgery: Creating new challenges for the endoscopist. Gastrointest Endosc 2003; 57: 86-94 (Pubitemid 36236805)
6. El-Serag HB. Obesity and disease of the esophagus and colon. Gastroenterol Clin N Am 2005; 34: 63-82 (Pubitemid 40488732)
7. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211 (Pubitemid 41076753)
8. Sjostrom L, Larsson B, Backman L et al. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord 1992; 16: 465-479
9. Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995; 98: 115-117
10. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004; 80: 38-44 (Pubitemid 41115552)
11. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. Arch Intern Med 2006; 166: 2369-2374 (Pubitemid 44833363)
12. Martinez J, Sanchez-Paya J, Palazon JM et al. Is obesity a risk factor in acute pancreatitis? A meta-analysis. Pancreatology 2004; 4: 42-48 (Pubitemid 38453121)
13. Calle EE. Obesity and cancer. BMJ 2007; 335: 1107-1108 (Pubitemid 350247271)
14. Bergstrom A, Pisani P, Tenet V et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430 (Pubitemid 32049639)
15. Corley DA. Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut 2007; 56: 1493-1494 (Pubitemid 350033181)
16. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-878 (Pubitemid 43823511)
17. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-2225 (Pubitemid 46693749)
18. Berrington de GA, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003; 89: 519-523 (Pubitemid 37026437)
19. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578 (Pubitemid 351232031)
20. Corley DA, Kubo A, Levin TR et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133: 34-41 (Pubitemid 47031134)
21. Pischon T, Lahmann PH, Boeing H et al. Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920-931 (Pubitemid 44018922)
22. Patel AV, Rodriguez C, Bernstein L et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large US cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 459-466 (Pubitemid 40270112)
23. Giovannucci E. Obesity, gender, and colon cancer. Gut 2002; 51: 147 (Pubitemid 34791434)
24. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut 2002; 51: 191-194 (Pubitemid 34791445)
25. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003; 349: 926-928 (Pubitemid 37064764)
26. Blundell JE. Perspective on the central control of appetite. Obesity (Silver Spring) 2006; 14 Suppl 4: 160S-163S
27. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007; 132: 2116-2130 (Pubitemid 46693747)
28. Monteleone P, Bencivenga R, Longobardi N et al. Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab 2003; 88: 5510-5514 (Pubitemid 37452763)
29. Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body weight regulation. Cell Metab 2006; 4: 223-233 (Pubitemid 44307976)
30. Cummings DE, Shannon MH. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrin Metab 2003; 88: 2999-3002 (Pubitemid 36877461)
31. Le Roux CW, Aylwin SJ, Batterham RL et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114 (Pubitemid 43054062)
32. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948 (Pubitemid 37064767)
33. Batterham RL, Le Roux, CW, Cohen MA et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992 (Pubitemid 37034556)
34. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Report No.:WHO/NUT/NCD/98.1
35. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. Obes Res 1998; 6 Suppl 2: 1S-209S
36. National Institute of Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children, 2006. Available at: www.NICE.org.uk/CG43
37. Glenny AM, O'Meara S, Melville A et al. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 1997; 21: 715-737 (Pubitemid 27375887)
38. de Goederen-van der Meij S, Pierik RGJM, OudkerkPool M et al. Six months of balloon treatment does not predict the success of gastric banding. Obes Surg 2007; 17: 88-94
39. Schapiro M, Benjamin S, Blackburn G et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19- 21, 1987. Gastrointest Endosc 1987; 33: 323-327 (Pubitemid 17122437)
40. Fernandes M, Atallah AN, Soares BG et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 2007; 1: CD004931
41. Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis 2008; 26: 40-44 (Pubitemid 350308348)
42. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg 2008; 18: 1611-1617
43. Negrin Dastis S, Francois E, Deviere J et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy 2009; 41: 575-580
44. Melissas J, Mouzas J, Filis D et al. The intragastric balloon - smoothing the path to bariatric surgery. Obes Surg 2006; 16: 897-902 (Pubitemid 44133480)
45. Rucker D, Padwal R, Li SK et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199 (Pubitemid 350273303)
46. Christensen R, Kristensen PK, Bartels EM et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713 (Pubitemid 350100788)
47. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61: 19-27 (Pubitemid 40169806)
48. Rutten SJE, de Goederen-van der Meij S, Pierik RGJM, Mathus-Vliegen EMH. Changes in quality of life after balloon treatment followed by gastric banding in severely obese patients - the use of two different quality of life questionnaires. Obes Surg 2009 DOI 10.1007/s11695- 008-9732-3